VRTX — Vertex PharmaceuticalsFREE
Median target
$565
across the calls below
Implied return
+17.3%
median target vs. price
Coverage
33 analysts · 37 calls
within the date window
Consensus
26/6/1+25 net
Buy / Hold / Sell
Current analyst calls on VRTX
Each row is one analyst's live rating and price target. Sorted by implied return by default — click any column header to re-sort. By default only calls updated in the last 12 months are shown — change or clear the bound to see all.
37 of 53 calls shown
| Andrew Fein | – | – | – | H.C. Wainwright | Buy | $641 | +33.1% | Jul 7, 2026 | |
| Salveen Richter | – | – | – | Goldman Sachs | Buy | $641 | +33.1% | Jun 10, 2026 | |
| Terence Flynn | – | – | – | Morgan Stanley | Buy | $616 | +27.9% | May 5, 2026 | |
| Eliana Merle | – | – | – | Barclays | Buy | $615 | +27.7% | Jul 8, 2026 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $610 | +26.6% | Jul 8, 2026 | |
| Evan Seigerman | – | – | – | BMO Capital | Buy | $600 | +24.6% | Jul 7, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +24.6% | Mar 10, 2026 | |
| Jay Olson | – | – | – | Oppenheimer | Buy | $600 | +24.6% | May 5, 2026 | |
| Tazeen Ahmad | – | – | – | Bank of America Securities | Buy | $600 | +24.6% | Jul 13, 2026 | |
| Ying Huang | – | – | – | Bank of America Securities | Buy | $598 | +24.1% | Mar 10, 2026 | |
| Carter Gould | – | – | – | Cantor Fitzgerald | Buy | $590 | +22.5% | Jul 6, 2026 | |
| Geoff Meacham | – | – | – | Citi | Buy | $585 | +21.4% | Jul 7, 2026 | |
| Michael Yee | – | – | – | UBS | Buy | $585 | +21.4% | Jul 13, 2026 | |
| Akash Tewari | – | – | – | Jefferies | Buy | $580 | +20.4% | Mar 10, 2026 | |
| Naz Rahman | – | – | – | Maxim Group | Buy | $575 | +19.4% | Jul 9, 2026 | |
| William Pickering | – | – | – | Bernstein | Buy | $572 | +18.8% | May 5, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Buy | $570 | +18.3% | Jul 7, 2026 | |
| Danielle Brill | – | – | – | Truist Financial | Buy | $560 | +16.3% | Jul 13, 2026 | |
| Greg Harrison | – | – | – | Scotiabank | Hold | $558 | +15.8% | Feb 13, 2026 | |
| Louise Chen | – | – | – | Scotiabank | Buy | $558 | +15.8% | Jul 7, 2026 | |
| Mohit Bansal | – | – | – | Wells Fargo | Buy | $550 | +14.2% | Jul 6, 2026 | |
| Sadia Rahman | – | – | – | Wells Fargo | Buy | $550 | +14.2% | Jul 13, 2026 | |
| Andy Chen | – | – | – | Wolfe Research | Buy | $548 | +13.8% | Jan 6, 2026 | |
| Brian Abrahams | – | – | – | RBC Capital | Buy | $543 | +12.7% | May 5, 2026 | |
| Cory Kasimov | – | – | – | Evercore ISI | Buy | $535 | +11.1% | Jul 7, 2026 | |
| Liisa Bayko | – | – | – | Evercore ISI | Buy | $530 | +10.0% | Jan 23, 2026 | |
| David Risinger | – | – | – | Leerink Partners | Buy | $525 | +9.0% | Dec 29, 2025 | |
| Joon Lee | – | – | – | Truist Financial | Buy | $525 | +9.0% | Mar 11, 2026 | |
| Phil Nadeau | – | – | – | TD Cowen | Buy | $525 | +9.0% | Jul 7, 2026 | |
| Paul Matteis | – | – | – | Stifel Nicolaus | Hold | $466 | -3.3% | Feb 13, 2026 | |
| Whitney Ijem | – | – | – | Canaccord Genuity | Hold | $436 | -9.5% | Jul 6, 2026 | |
| Gena Wang | – | – | – | Barclays | Hold | $414 | -14.1% | Nov 10, 2025 | |
| Brian Skorney | – | – | – | Robert W. Baird | Sell | $350 | -27.3% | Jul 7, 2026 | |
| Danielle Brill | – | – | – | Truist Financial | Buy | – | – | Jul 7, 2026 | |
| Hans Engel | – | – | – | Erste Group | Hold | – | – | May 5, 2026 | |
| Joseph Stringer | – | – | – | Needham | Hold | – | – | Jul 7, 2026 | |
| Myles Minter | – | – | – | William Blair | Buy | – | – | Jul 7, 2026 |
Analyst track records are Premium — unlock every analyst's score, rank and success rate.
Implied return is the move the stock would make if the analyst's target were hit. These are forward-looking predictions, not realized returns. Only reliable-basis calls are included; the consensus figures above are computed from the calls in this table.
VRTX elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-07-02 | Insiders | Mckechnie DuncanEVP, Chief Commercial Of | Insider sale | 1.5K sh @ $519.00 · planned trade | $800K |
| 2026-07-02 | Insiders | Tatsis OuraniaEVP, Chief Reg. & Qualit | Insider sale | 1.5K sh @ $524.99 · planned trade | $787K |
| 2026-07-01 | Insiders | Liu JoyEVP and Chief Legal Offi | Insider sale | 828 sh @ $502.71 · planned trade | $416K |
| 2026-06-26 | Insiders | Bozic CarmenOfficer | Insider sale | 596 sh @ $482.50 · planned trade | $288K |
| 2026-06-18 | Insiders | Bozic CarmenOfficer | Insider sale | 1.0K sh @ $462.17 · planned trade | $471K |
| 2026-06-15 | Insiders | Bozic CarmenOfficer | Insider sale | 4.1K sh @ $450.00 · planned trade | $1.8M |
| 2026-06-05 | Insiders | Bozic CarmenOfficer | Insider sale | 1.7K sh @ $450.00 · planned trade | $785K |
| 2026-01-30 | Executive | Mody, ArjunDeputy Commissioner | Sale | Vertex Pharmaceuticals, Inc. (VRTX) | $1,001 - $15,000 |
| 2026-01-29 | Congress | David J. TaylorOH-OH02 | Sale | since trade +1.9%, vs market +9.3% | $1K–$15K |
| 2025-06-11 | Congress | Lisa McClainMI-MI09 | Sale | since trade +7.2%, vs market +22.3% | $1K–$15K |
More: congressional trades on VRTX · insider activity · executive branch · trending